Trial · NCT03613532
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MTD of Venetoclax with Busulfan and Fludarabine | 37 Days | Determine safe dose and schedule of venetoclax |
| Primary | MTD of Venetoclax with Azacitidine as Maintenance Therapy | 28 Days from Maintenance Therapy Start | Determine safe dose and schedule of venetoclax |
| Primary | MTD of Venetoclax with Decitabine/cedazuridine as Maintenance Therapy | 28 Days from Maintenance Therapy Start | Determine safe dose and schedule of venetoclax |
| Secondary | Overall Survival | 12 Months | Time from treatment start until death |
| Secondary | Progression Free Survival | 12 Months | Time from treatment start until relapse |
| Secondary | Overall Response Rate | At day 100, 6 months and 12 months | IWG response criteria |
| Secondary | Remission Duration Rate | from start of the treatment until disease relapse (assessed at day 100, 6 months and 12 months) | Duration of remission from treatment start until relapse |
| Secondary | Rate of Disease Relapse | 12 Months | Frequency of disease recurrence on trial |
| Secondary | Rate of Non-Relapse Mortality | 12 Months | Frequency of death that is not due to disease recurrence on trial |
| Secondary | Donor granulocyte chimerism percentage | 28 Days Post-Transplant | Percentage of donor blood cells |
| Secondary | Donor granulocyte chimerism percentage | 100 days Post-Transplant | Percentage of donor blood cells |
| Secondary | Donor granulocyte chimerism percentage | 12 Months Post-Transplant | Percentage of donor blood cells |
| Secondary | Cumulative incidence of acute graft versus host disease (GVHD) and chronic GVHD following allo-HCT | 12 Months | Frequency of GVHD events |
| Secondary | Number of Maintenance Treatment Cycles Safely Administered | From Initiation of Maintenace Therapy up to 12 months | Maintenance Treatment Cycles |
| Secondary | Compare Incidences of Mortality and Survival Between Participants in Part 1, Part 2 and Part 3 | 12 months | Compare cumulative instances of mortality and survival between participants on Part 1, Part 2 and Part 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03613532/registered